3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
10
Thoracic
9
Sarcoma
4
Head & Neck
3
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Urinary Bladder Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Docetaxel
191
Gemcitabine
148
Prednisone
142
pembrolizumab
125
enzalutamide
119
Abiraterone Acetate
108
Nivolumab
107
Cisplatin
103
Magnetic Resonance Spectroscopy
100
Radiotherapy
95
Sunitinib
94
Leuprolide
91
Carboplatin
82
Specimen Handling
71
Androgen Antagonists
63
bicalutamide
60
Radiosurgery
60
Paclitaxel
59
Goserelin
59
Ipilimumab
57
Bevacizumab
57
apalutamide
53
Sorafenib
53
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
51
Everolimus
49
cabozantinib
48
abiraterone
46
atezolizumab
45
cabazitaxel
43
durvalumab
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
trilaciclib
×
Genitourinary
×
Clear all
NCT04887831
2025-09-08
PRESERVE3
G1 Therapeutics, Inc.
Phase 2
Terminated
92 enrolled
24 charts